Tevimbra plus chemotherapy reduced the risk of death by 20% compared with placebo plus chemotherapy. The Food and Drug Administration (FDA) has approved Tevimbra ® (tislelizumab-jsgr) for use in ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

The transition from the esophagus to the stomach is a delicate region from a medical point of view, often associated with pathological disorders leading to cancer. An international research team has ...

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer. The approval ...

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this ...

Credit: Astellas. Vyloy is a claudin 18.2-directed cytolytic antibody. In clinical trials, CLDN18.2 positivity was determined by immunohistochemistry on gastric or GEJ tumor tissue specimens with the ...

This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This abstract does not include a full text component.

Please provide your email address to receive an email when new articles are posted on . Sintilimab plus chemotherapy conferred longer median OS compared with placebo plus chemotherapy. Patients with ...